Lv5
1000 积分 2024-03-18 加入
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
1个月前
已完结
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
1个月前
已完结
Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SL
1个月前
已完结
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
3个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
3个月前
已完结
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology
4个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
6个月前
已完结
Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
6个月前
已完结
A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances
6个月前
已完结
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN
6个月前
已完结
皖公网安备34019202002308
